Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Amrubicin
Sponsor: SCRI Development Innovations, LLC
Collaborators: Celgene